drugset / Trial / NCT04867434
Efficacy and Safety of RZL-012 on Submental Fat Reduction
RandomizedParallel-groupDouble-blindTreatment
Summary
A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo on Day 0. They will be monitored for safety and efficacy over 84 days.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2022-04-20
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | UTENPANIUM | Small molecule | 5.1 mg | — |
| Comparator | UTENPANIUM | Small molecule | 7.5 mg | — |
Indications
No indication recorded.